Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic allications
AssigneeBracco International B.V.
InventorsRamachandra S. Ranganathan, Helen Fan, Michael F. Tweedle
Life of this patent
Estimating the term…
Abstract
The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.
Claims138
A compound having the following chemical structure:
- 9
- wherein M is 99mTc, 51 Cr, 67Ga, 68Ga, 111In, 168Yb, 140La, 90Y, 88Y, 86Y, 153Sm, 166Ho, 165Dy, 64Cu, 67Cu, 97Ru, 103Ru, 186Re, 188Re, 203Pb, 211Bi, 212Bi, 213Bi, 214Bi, 215Bi, 177Lu, chromium (III), manganese (II), iron (II), iron (III), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III), gadolinium (III), terbium, (III), dysprosium (III), holmium (III), erbium (III) or ytterbium (III);
- and
- X is CH2, an amino acid, a peptide, a protein, or an antibody.
A compound having the structure:
- 49
- wherein X is CH2, an amino acid, a peptide, a protein, or an antibody.
A compound having the structure:
- 54
- wherein X is CH2, an amino acid, a peptide, a protein, or an antibody.
A compound having the structure:
- 59
- wherein X is Cl2, an amino acid, a peptide, a protein, or an antibody.
A compound having the structure:
- 66
A compound having the structure:
- 94
A compound having the following structure:
- 116
A compound having the structure:
- 136
A kit for the preparation of a radiopharmaceutical, the kit comprising an antioxidant covalently bound to a complexing ligand.
A kit for the preparation of a radiopharmaceutical, the kit comprising a compound having the structure:
- 162
- wherein X is CH2, an amino acid, a peptide, a protein, or an antibody
A method of stabilizing a radiopharmaceutical ligand, the method comprising covalently binding an antioxidant to a radiopharmaceutical ligand optionally including a targeting molecule.
Dependencies are inferred from the claim text.